An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.

doi:10.1080/17474086.2023.2174521

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.

Expert review of hematology - 1 Feb 2023

Venugopal Sangeetha, Xie Zhuoer, Zeidan Amer M

Abstract excerpt

INTRODUCTION: The past decade has seen a sea change in the AML landscape with vastly improved cognizance of molecular pathogenesis, clonal evolution, and importance of measurable residual disease. Since 2017, the therapeutic armamentarium of AML has considerably expanded with the approval of midostaurin, enasidenib, ivosidenib, gilteritinib, and venetoclax in combination with hypomethylating agents and others....

Topics

Humans
Leukemia, Myeloid, Acute
Mutation
Recurrence
Bridged Bicyclo Compounds, Heterocyclic

Source

Open in PubMed

Identifiers

PMID: 36718500
DOI: 10.1080/17474086.2023.2174521

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics